JAK Inhibitors in Giant Cell Arteritis: A Systematic Review and Meta-Analysis Supporting Upadacitinib Efficacy and Glucocorticoid Reduction (ACR Convergence 2026) - Sep 8, 2026 - Abstract #176; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; " Four GCA studies were included: one phase 3 RCT, one prospective pilot study, and two retrospective real-world cohorts evaluating upadacitinib, baricitinib, and tofacitinib...Glucocorticoid dose reduction data in GCA were limited: at 6 months, one study reported a mean prednisone-equivalent reduction of 7.98 mg/day (95% CI −12.38 to −3.58; n=14)... JAK inhibition was associated with clinically meaningful response and complete-response rates in GCA, with manageable safety signals and evidence of glucocorticoid sparing. The strongest evidence supports upadacitinib 15 mg, driven by SELECT-GCA, while smaller real-world cohorts suggest broader class activity in relapsing or refractory GCA. Pooled ORR estimates should be interpreted cautiously because they derive from small observational cohorts, whereas complete-response estimates are strongly influenced by the phase 3 upadacitinib dataset."
Retrospective data • Review • Giant Cell Arteritis • Herpes Zoster • Immunology • Inflammation • Varicella Zoster
|
|
Mireia Sanmartin Martinez1; Roxana González Mazarío2; Jorge Juan Fragío Gil3; Pablo Martínez Calabuig4; Ivan Jesus Lorente Betanzos2; Berta Gomez Correas2; Pablo Garcia Castro2; Juan Jose Lerma Garrido2; Isabel Martinez Cordellat2; Amalia Rueda Cid2; Isabel Balaguer Trull2; Lucia Francés Ruíz2; Cristina Campos Fernández3
|